Complete financial analysis of Biodexa Pharmaceuticals Plc (BDRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodexa Pharmaceuticals Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- HealthEquity, Inc. (HQY) Income Statement Analysis – Financial Results
- Mind Medicine (MindMed) Inc. (MMED.NE) Income Statement Analysis – Financial Results
- Tycoons Worldwide Group (Thailand) Public Company Limited (TYCN.BK) Income Statement Analysis – Financial Results
- Shenzhen Xinyichang Technology Co., Ltd. (688383.SS) Income Statement Analysis – Financial Results
- Eline Entertainment Group, Inc. (EEGI) Income Statement Analysis – Financial Results
Biodexa Pharmaceuticals Plc (BDRX)
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 381.00K | 699.00K | 578.00K | 343.00K | 674.00K | 1.94M | 989.00K | 1.32M | 1.38M | 157.00K | 147.00K | 0.00 |
| Cost of Revenue | 4.07M | 5.11M | 4.65M | 6.07M | 7.84M | 9.36M | 8.33M | 7.73M | 70.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.69M | -4.41M | -4.08M | -5.73M | -7.17M | -7.42M | -7.34M | -6.41M | 1.31M | 157.00K | 147.00K | 0.00 |
| Gross Profit Ratio | -967.45% | -631.19% | -705.19% | -1,669.10% | -1,063.65% | -382.92% | -742.16% | -484.28% | 94.91% | 100.00% | 100.00% | 0.00% |
| Research & Development | 4.07M | 5.11M | 4.65M | 16.15M | 7.84M | 9.36M | 9.83M | 7.73M | 8.71M | 5.44M | 2.84M | 1.65M |
| General & Administrative | 4.34M | 4.54M | 2.95M | 4.96M | 3.84M | 4.39M | 4.27M | 3.25M | 2.08M | 4.23M | 1.81M | 2.36M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 6.00K | 323.00K | 0.00 | 170.00K | 0.00 | 605.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 4.34M | 4.54M | 2.95M | 4.96M | 4.16M | 4.39M | 4.44M | 3.25M | 2.69M | 4.23M | 1.81M | 2.36M |
| Other Expenses | -4.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.33M | 4.05M | 1.99M | 17.71M | 3.67M | 4.39M | 5.54M | 2.07M | 12.59M | 9.84M | 4.65M | 4.01M |
| Cost & Expenses | 8.40M | 9.16M | 6.64M | 23.78M | 11.51M | 13.75M | 13.87M | 9.80M | 12.66M | 9.84M | 4.65M | 4.01M |
| Interest Income | 83.00K | 24.00K | 44.00K | 33.00K | 89.00K | 585.00K | 94.00K | 91.00K | 48.00K | 153.00K | 384.00K | 557.00K |
| Interest Expense | 41.00K | 53.00K | 44.00K | 34.00K | 97.00K | 587.00K | 109.00K | 0.00 | 0.00 | 161.00K | 248.00K | 0.00 |
| Depreciation & Amortization | 283.00K | 343.00K | 403.00K | 1.22M | 1.29M | 1.11M | 1.17M | 4.35M | 736.00K | 321.00K | 246.00K | 194.00K |
| EBITDA | -7.16M | -7.40M | -5.66M | -22.22M | -9.54M | -10.70M | -10.61M | -5.30M | -10.49M | -9.36M | -4.25M | -3.81M |
| EBITDA Ratio | -1,879.53% | -1,252.50% | -1,173.88% | -2,790.67% | -1,533.53% | -552.32% | -1,072.70% | -400.76% | -680.44% | -4,709.55% | -2,893.20% | 0.00% |
| Operating Income | -8.01M | -8.93M | -7.00M | -10.67M | -11.32M | -11.82M | -11.78M | -9.65M | -10.09M | -7.72M | -4.50M | -4.01M |
| Operating Income Ratio | -2,103.41% | -1,277.83% | -1,210.73% | -3,111.08% | -1,679.23% | -609.65% | -1,190.70% | -729.55% | -733.96% | -4,914.01% | -3,060.54% | 0.00% |
| Total Other Income/Expenses | 529.00K | 444.00K | 892.00K | -430.00K | 395.00K | -585.00K | -1.19M | 1.26M | 1.69M | -153.00K | -384.00K | -557.00K |
| Income Before Tax | -7.49M | -8.49M | -6.11M | -23.47M | -10.92M | -12.40M | -12.97M | -8.39M | -11.23M | -9.84M | -4.88M | -4.57M |
| Income Before Tax Ratio | -1,964.57% | -1,214.31% | -1,056.40% | -6,842.57% | -1,620.62% | -639.83% | -1,311.43% | -634.01% | -816.87% | -6,267.52% | -3,321.77% | 0.00% |
| Income Tax Expense | -406.00K | 832.00K | 646.00K | 1.28M | 1.79M | 2.03M | 1.27M | 2.23M | 1.13M | 1.02M | 799.00K | 571.00K |
| Net Income | -7.08M | -7.66M | -5.46M | -22.19M | -9.14M | -10.37M | -11.71M | -6.16M | -10.10M | -8.82M | -4.08M | -3.99M |
| Net Income Ratio | -1,858.01% | -1,095.28% | -944.64% | -6,469.10% | -1,355.79% | -534.98% | -1,183.52% | -465.68% | -734.47% | -5,619.11% | -2,778.23% | 0.00% |
| EPS | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -224.13 | -619.72 | -542.31 | -4.14K | -3.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 31.59K | 12.35K | 10.07K | 5.36K | 2.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Biodexa Pharmaceuticals stock more than doubled on Tuesday: explore why
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) opened more than 100% up on Tuesday after reporting encouraging Phase 2 data for eRapa.
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
May 21, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting Overall 83%...
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today?
Biodexa Pharmaceuticals (NASDAQ: BDRX ) stock is rocketing higher on Tuesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 15.8 million shares of BDRX stock changing hands as of this writing.
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
Registrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year. The candidate was developed with private funds and acquired by Biodexa, its second portfolio expansion in less than six months, and is...
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
April 30, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC,...
Why Is Biodexa (BDRX) Up 70% Today?
Oncology specialist Biodexa (NASDAQ: BDRX ) soared on Friday as the company disclosed the entering of an exclusive worldwide license to develop and commercialize a key therapeutic. Fundamentally, the announcement sent BDRX stock flying up about 70% in the late...
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding...
Preliminary Results for the Year Ended 31 December 2023
19 April 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of...
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?
Biodexa Pharmaceuticals (NASDAQ: BDRX ) stock is rising higher on Thursday after the clinical-stage biopharmaceutical company announced positive results from one of its brain cancer treatments. According to a press release from the company, early trials of MTX110 are showing...
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
Topline Results For Progression-Free Survival Expected In Q2 2024 CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pediatric patients...
Source: https://incomestatements.info
Category: Stock Reports